Gusacitinib hydrochloride is under clinical development by Libertas Bio and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Gusacitinib hydrochloride’s likelihood of approval (LoA) and phase transition for Hand Dermatitis took place on 26 Oct 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Gusacitinib hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Gusacitinib hydrochloride overview
Gusacitinib hydrochloride (ASN-002) is under development for the treatment of hand dermatitis, atopic dermatitis, chronic dermatitis and systemic lupus erythematosus. The drug candidate is administered orally as a tablet. The drug candidate acts by targeting spleen tyrosine kinase (SYK) and Janus kinase (JAK).
The drug candidate was also under development for the treatment of rheumatoid arthritis, relapsed/refractory non-Hodgkin lymphomas including follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, myelofibrosis, multiple myeloma, erythroleukemia, bladder cancer and Peripheral T-Cell Lymphomas (PTCL).
Quick View Gusacitinib hydrochloride LOA Data
|Highest Development Stage|